Results 101 to 110 of about 53,280 (246)

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source

Tofacitinib inhibits ox-LDL-induced adhesion of THP-1 monocytes to endothelial cells

Artificial Cells, Nanomedicine, and Biotechnology, 2019
Atherosclerosis is a chronic inflammatory disease of the blood vasculature. Endothelial dysfunction is an early event in the development of atherosclerosis and the endothelium plays an important role in the innate immune defense in the pathology of ...
Xiaoyang Yang, Mengjie Wan, Zhiyong Cheng, Zhiming Wang, Qingxia Wu   +4 more
doaj   +1 more source

Effects of naringenin on the pharmacokinetics of tofacitinib in rats

Pharmaceutical Biology, 2020
Context Naringenin and tofacitinib are often used together for treatment of rheumatoid arthritis in Chinese clinics. Objective This experiment investigates the effect of naringenin on the pharmacokinetics of tofacitinib in rats.
Bo Wang, Jiquan Shen, Quan Zhou, Deru Meng, Youwu He, Feifei Chen, Shuanghu Wang, Weiping Ji   +7 more
doaj   +1 more source

Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis

Rheumatology &Autoimmunity, EarlyView.
Patient‐reported outcomes (PROs) were compared among rheumatoid arthritis patients who maintained low disease activity or remission for at least 6 months based on the disease‐modifying antirheumatic drug (DMARD)administered. Even with comparable disease activity, methotrexate (MTX) group, biological/targeted synthetic DMARDs (b/tsDMARDs), particularly ...
Masafumi Sugiyama, Saki Okuda‐Tsuchimoto, Takashi tsuchimoto, Koji Kinoshita, Itaru Matsumura   +4 more
wiley   +1 more source

Type I interferon overactivation in sera of patients with anti‐MDA5‐positive dermatomyositis‐associated interstitial lung disease

Rheumatology &Autoimmunity, EarlyView.
Sera from patients with anti‐MDA5‐positive dermatomyositis‐associated interstitial lung disease (ILD) exhibit significantly higher type I interferon (IFN‐I) bioactivity and interferon‐stimulated gene‐inducing activity compared to anti‐ARS‐positive ILD and healthy controls.
Shohei Nakamura, Yasuhiro Katsumata, Yuko Okamoto, Masayoshi Harigai   +3 more
wiley   +1 more source

Chronic Myeloid Leukemia in a Patient Receiving Tofacitinib: A Case Report and Literature Review

Case Reports in Rheumatology, 2019
Background. Tofacitinib is a new oral Janus kinase inhibitor that has shown promising clinical benefit in various rheumatologic diseases. However, many concerns related to the development of malignancies have been reported with its use. Case Presentation.
Georgio Medawar, Joseph Chahrouri, Rabih Said   +2 more
doaj   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Tofacitinib in acute severe ulcerative colitis: review addressing seven key unmet needs

Therapeutic Advances in Gastroenterology
Tofacitinib, an oral Janus kinase (JAK) inhibitor, shows promise as a rescue therapy for acute severe ulcerative colitis (ASUC), a life-threatening condition marked by high colectomy rates.
Chuong Dinh Nguyen, Luan Minh Dang, Thong Duy Vo, Hoang Huu Bui, Eun Soo Kim, Joyce Wing Yan Mak, Choon Jin Ooi   +6 more
doaj   +1 more source

Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Arthritis Research & Therapy, 2018
Background Tofacitinib is the first oral Janus kinase inhibitor approved for the treatment of rheumatoid arthritis (RA). We compared the effectiveness and safety of tofacitinib, disease-modifying antirheumatic drugs (DMARDs), tumor necrosis factor ...
Marina Amaral de Ávila Machado, Cristiano Soares de Moura, Steve Ferreira Guerra, Jeffrey R. Curtis, Michal Abrahamowicz, Sasha Bernatsky   +5 more
doaj   +1 more source

The safety and immunogenicity of live Zoster Vaccination in patients with rheumatoid arthritis before starting Tofacitinib: a randomized phase II trial [PDF]

, 2017
Objective Patients with rheumatoid arthritis (RA) are at increased risk of herpes zoster, and vaccination is recommended for patients ages 50 years and older, prior to starting treatment with biologic agents or tofacitinib.
Aletaha, Aletaha, Assen, Burmester, Curtis, Fleischmann, Fleischmann, Friedman, Hales, Harpaz, Heijde, Jung, Kremer, Lee, Levin, Levin, Oxman, Perry, Pierson, Rubin, Ruderman, Schmader, Singh, Singh, Smolen, Vollenhoven, Winthrop, Wollenhaupt, Wollenhaupt, Yun   +29 more
core   +2 more sources